Loading patent…
AssigneeArrowhead Pharmaceuticals, Inc.
InventorsBrian Bettencourt, Shanthi Ganesh, Elizabeth George, Dieter Huesken, Stuart Milstein, Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
Estimating the term…
The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic imflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.
A composition comprising an RNAi agent for inhibiting expression of an EPAS1 gene comprising a sense strand and an antisense strand, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO:61 differing by 0 or 1 nucleotides, and the sense strand comprises the nucleotide sequence of SEQ ID NO:42 differing by 0 or 1 nucleotides, and wherein the RNAi agent comprises at least one 2′-modified nucleotide on the antisense strand.
Dependencies are inferred from the claim text.